CNM-Au8 in Amyotrophic Lateral Sclerosis

Overview of attention for article published in JAMA: Journal of the American Medical Association, February 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 8 news outlets
blogs: 4 blogs
twitter: 10 X users
facebook: 3 Facebook pages

video: 1 YouTube creator
bluesky: 4 Bluesky users
podcasts: 2 podcasts

Readers on

mendeley: 30 Mendeley

So far, Altmetric has seen 5 Bluesky posts from 4 Bluesky users, with an upper bound of 23,195 followers.

(it just didn’t work for ALS) https://bsky.app/profile/did:plc:q5ogl3twkcqyhvz4zebonw3z/post/3llrdvuj7352o

CNM-Au8, an oral suspension of catalytically active gold particles, did not improve the primary efficacy outcome of amyotrophic lateral sclerosis disease progression. https://ja.ma/4iSF3n4

No significant benefit of CNM-Au8 on amyotrophic lateral sclerosis disease progression was observed over 24 weeks. jamanetwork.com/journals/jam...

CNM-Au8 in ALS - HEALEY Platform Trial outcomes No significant positive effects. Government funded EAP underway. Previous trials showed efficacy in longer-term follow-up - Healey only 6-months Larger Phase 3 trial under consideration and Clene in discus…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity, including 1 additional Bluesky posts.